XXVI Congreso de la SEIOMM: consulte el programa de los HOT TOPICS, el más completo resumen del ASBMR

  1. Inicio
  2. »
  3. Noticias SEIOMM
  4. »
  5. XXVI Congreso de la SEIOMM: consulte el programa de los...

Los HOT TOPICS se celebrarán el primer día del XXVI Congreso de la SEIOMM, el miércoles día 5 de octubre, a partir de las 9 de la mañana. Los HOT TOPICS son, como bien saben nuestros socios, el más completo resumen que se hace del Annual Meeting de la American Society of Bone and Mineral Research (ASBMR), una excelente oportunidad para la actualización de conocimientos.

Los HOT TOPICS son una iniciativa de la SEIOMM que podemos ofrecerles gracias a la colaboración de Gebro Pharma.

INSCRIPCIÓN. Atención, la pasarela de inscripción se cerrará el lunes, 3 de octubre.

Para asistir, es necesario formalizar la inscripción en este enlace: http://www.seiomm.eu/inscripcion.aspx?IdCongreso=124&P=J


09:00 – 09:05. Presentación del curso

Dr. José A. Riancho Moral, Dra. Pilar Peris Bernal


09:05 – 09:25. Vitamina D: ¿qué hay de nuevo?

Dr. José L. Pérez Castrillón

[1051] Effects of Omega-3 Fatty Acid Supplementation on Incident Fractures in Midlife and Older Adults Enrolled in VITamin D and OmegA-3 TriaL (VITAL). September 11, 10:00 AM-10:15 AM.

[1068] Intestinal Calcium Absorption Decreases After Laparoscopic Sleeve Gastrectomy Despite Optimization of Vitamin D Status. September 11, 03:45 PM-04:00 PM.

RESUMIR: Symposium on Vitamin D: Lessons Learned from Recent RCTs September 12, 2022, 08:00 AM: Rethinking the Use of Supplemental Vitamin D for Bone Health: Findings from Large Randomized Controlled Trials (RCTs) 08:00 AM-08:20 AM; Vitamin D and non-musculoskeletal health outcomes: evidence from randomized controlled trials 08:20 AM-08:40 AM; Comprehensive conclusions regarding health effects from Vitamin D as based on RCTs and Mendelian Randomization studies).

09:25 – 09:45. Valoración del riesgo de fractura; FRAX o no FRAX.

Dra. Cristina Carbonell Abella

[1017] Global Epidemiology of Hip Fracture – Secular Trends of Incidence, Treatment Rate, and Mortality from 2005 to 2018; A Multinational Real-world Study with Common Data Model. September 9, 12:00 PM-12:15 PM.

[1020] Adjusting FRAX Estimates of Fracture Probability Based Upon a Positive Vertebral Fracture Assessment: The Manitoba BMD Registry. September 9, 12:45 PM-01:00 PM.

[1114] Performance of FRAX and Garvan Fracture Risk Assessment Tools in Hip Fracture Prediction in US Adults Aged 80 Year and Older: Findings from the Study of Osteoporotic Fractures (SOF) and Osteoporotic Fractures in Men (MrOS) Study. September 12, 12:15 PM-12:30 PM.

RESUMIR: ASBMR Task Force on Clinical Algorithms, September 09, 2022, 01:45 PM: Task Force on incorporating race/ethnicity into clinical algorithms: An update (September 9, 01:45 PM-02:45 PM)

09:45 – 10:05. Agentes anabólicos: indicaciones y contraindicaciones.

Dr. Carlos Gómez Alonso

[1025] Evaluation of Romosozumab’s Effects on Bone Marrow Adiposity in Postmenopausal Osteoporotic Women: Results from The FRAME Bone Biopsy Sub-Study. September 10, 11:00 AM-11:15 AM.

[1053] KER-012, A Modified ActRIIB Ligand Trap, Administered To Healthy, Postmenopausal Women Was Generally Well Tolerated And Increased Biomarkers Of Bone Formation Supportive Of A Bone Anabolic Mechanism. September 11, 10:30 AM-10:45 AM.

[1054] Comparative Histomorphometric Effects of Teriparatide, Denosumab, or Both on Postmenopausal Osteoporotic Women: A Randomized Controlled Trial. September 11, 10:45 AM-11:00 AM.

[1055] One Year of Romosozumab Followed by One Year of Denosumab Compared With Two Years of Denosumab: BMD and Fracture Results From the FRAME and FRAME Extension Studies. September 11, 11:00 AM-11:15 AM.

[1076] Romosozumab Efficacy in Postmenopausal Women Without Prior Fracture Who Fulfill AACE Criteria for Osteoanabolic Therapy: Post-Hoc Analysis of Clinical Trial Data. September 11, 03:15 PM-03:30 PM.

10:05 – 10:15. Discusión


10:15 – 10:35. Biología neuro-cardio-esquelética

Dr. Guillermo Martínez Díaz-Guerra

[1022] Myocardial Infarction and Stroke Risks Among Patients Who Initiated Treatment with Denosumab or Zoledronic Acid for Osteoporosis. September 10, 10:15 AM-10:30 AM.

[1038] Muscle Strength and Physical Performance are associated with risk of Post Fracture Mortality but not Subsequent Fracture in Men. September 10, 10:30 AM-10:45 AM.

[1021] Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomization. September 10, 10:00 AM-10:15 AM.

RESUMIR: Special Session: Neuro-Skeletal Biology, September 09, 2022, 01:45 PM: Role of sensory nerves in bone development and repair, September 9, 01:45 PM-02:15 PM; The intersection of diabetic neuropathy and bone disease – which comes first? September 9, 02:15 PM-02:45

10:35 – 10:55. Nuevas técnicas diagnósticas en la patología metabólica ósea.

Dr. Luis del Rio Barquero

[1113] Artificial Intelligence Based Diagnostic Software for Atypical Femur Fractures. September 12, 12:00 PM-12:15 PM.

[1117] Deep Learning Using Only Three-Dimensional High-Resolution Images of Bone and Soft Tissue Provides a Structural Fragility Score Which Predicts Incident Fractures. September 12, 11:45 AM-12:00 PM.

[1089] Diabetes Mellitus Is Associated with Greater Osteoporotic Fracture Risk Partly Independent of Fat Mass and BMD: Prospective Findings from UK Biobank. September 12, 10:30 AM-10:45 AM.

Welcome Reception and Plenary Poster Session:

[FRI-471] Crystal Bone: Validation of a Novel AI/ML Algorithm in the Optum Reliant dataset to Identify Patients at Risk of Osteoporotic Fracture in the Next 2 Years. September 9, 05:30 PM-07:00 PM.

[FRI-507] Machine Learning for Automated Abdominal Aortic Calcium Scoring and Prediction of Cardiovascular Outcomes in Routine Clinical Practice: The Manitoba BMD Registry. September 9, 05:30 PM-07:00 PM.

10:55 – 11:15. Efectos mecánicos y nuevas interacciones celulares en hueso

Dra. Arancha Rodríguez de Gortázar

[1041] Bone is sensor and acute responder to inflammation through rapid secretion of Lipocalin 2. September 11, 10:00 AM-10:15 AM.

[1046] Dual beneficial effects on bone and whole-body glucose homeostasis by genetic or pharmacological activation of the hypoxia signaling pathway. September 11, 10:00 AM-10:15 AM.

[1003] Identification of a Novel Skeletal Stem Cell where Adipocyte versus Osteoblast Lineage Commitment occurs. September 9, 12:15 PM-12:30 PM

[1074] Identification of AdipoQ+ bone marrow cells as the major cellular source of M-CSF that dominates bone marrow macrophage development, osteoclastogenesis and bone mass. September 11, 04:00 PM-04:15 PM

RESUMIR: Basic Symposium: Mechanobiology and Piezo Channels: Insights from the Outside, September 09, 2022, 03:00 PM: Mechanosensing in skeletal progenitors, September 9, 03:00 PM-03:30 PM; Force sensing by Piezo channels in cardiovascular biology September 9, 03:30 PM-04:00 PM.

11:15– 11:25. Discusión

11:25 – 11:40. Pausa


11:40 – 12:00. Biomarcadores óseos y terapias emergentes en distintas enfermedades óseas.

Dra. Nuria Guañabens Gay

[1040] High serum osteoprotegerin levels are associated with more rapid decline of bone density, microarchitecture and strength in older men – the prospective STRAMBO study. September 10, 11:00 AM-11:15 AM.

[1056] RANKL Inhibition Decreases Fibrous Cell Proliferation and Increases Lesional Bone Formation in Fibrous Dysplasia. September 11, 10:00 AM-10:15 AM.

[1044] Bone targeted bisphosphonate-conjugated antibiotics to eradicate Staphylococcus aureus biofilm within the osteocyte lacuno-canalicular network of infected cortical bone in chronic osteomyelitis. September 11, 10:45 AM-11:00 AM.

[1107] GDF15 and the risk of hip fracture. September 12, 11:45 AM-12:00 PM.

[1112] Changes in BMD and Bone Turnover Markers Following Discontinuation of Setrusumab After 1 Year of Treatment in Adults with Osteogenesis Imperfecta. September 12, 11:45 AM-12:00 PM.

12:00 – 12:20. El reto de la retirada de denosumab.

Dr. Esteban Jodar Gimeno

[1018] Long-term Denosumab Therapy and Subsequent Zoledronate Treatment: Observations in a Real-World Setting. September 9, 12:15 PM-12:30 PM.

[1078] Comparison of Alendronate versus Raloxifene after Denosumab Discontinuation (CARD): A Randomized Controlled Trial. September 11, 03:45 PM-04:00 PM.

[1016] Comparison of effectiveness of denosumab versus bisphosphonates in a registry-ased, real-world cohort study. September 9, 11:45 AM-12:00 PM.

RESUMIR: ASBMR/ECTS Plenary Symposium: The Challenge of Denosumab Withdrawal September 10, 2022, 03:15 PM: Denosumab discontinuation – clinical challenges and possible solutions, September 10, 03:15 PM-03:30 PM; Humanized RANKL mice to study rebound resorption, September 10, 03:30 PM-03:50 PM, Denosumab withdrawal – insights from pre-clinical investigations, September 10, 03:50 PM-04:10 PM

12:20 – 12:40. El Microambiente óseo.

Dr. Manuel Naves Díaz

[1008] Paracrine FGF23 Signaling Suppresses Erythropoiesis in Iron Deficiency Anemia. September 9, 12:15 PM-12:30 PM

[1110] Emerging role of FGF23 in the regulation of metabolic homeostasis.
September 12, 12:30 PM-12:45 PM.

[1062] Single cell proteomic analysis reveals senotherapeutic effecs of zoledronic acid on bone marrow pre-osteoclastic cells. September 11, 03:30 PM-03:45 PM.

RESUMIR: The many faces of skeletal stem cells, September 10, 08:00 AM-09:30 AM

12:40 – 12:50. Discusión


12:50 – 13:10. Consecuencias esqueléticas de la diabetes y la obesidad.

Dr. Manuel Muñoz Torres

[1088] Diabetes mellitus and the benefit of bisphosphonates therapy on fracture risk. September 12, 10:15 AM-10:30 AM.

[1090] The Clinical Relevance of Type 2 Diabetes for Fracture Risk – a Nationwide Cohort Study of Swedish Men and Women. September 12, 10:45 AM-11:00 AM.

RESUMIR: Plenary Symposium: Skeletal Consequences of Diabetes September 11, 2022, 04:45 PM, Increased fracture risk with diabetes: clinical challenges September 11, 04:45 PM-05:10 PM:The role of cellular senescence in mediating skeletal fragility in type II diabetes, September 11, 05:10 PM-05:35 PM; Bone fragility in diabetes – from mechanisms to novel therapies, September 11, 05:40 PM-06:00 PM.

13:10 – 13:30. Métodos de vanguardia para descubrir genes que controlan la densidad ósea y los riesgos de fracturas en humanos.

Dr. Xavier Nogués Solán

[1015] Single Cell Transcriptomic Analysis Highlights Potential New Mef2C targets In Bone Subpopulations. September 9, 12:45 PM-01:00 PM

[1116] Metagenomic Shotgun Sequencing of the Gut Microbiome in Two Cohort Studies and Associations with Skeletal Phenotypes and Cytokine Concentrations. September 12, 11:30 AM-11:45 AM.

RESUMIR: Special Session: Cutting Edge Methods to Discover Genes that Control Bone Density and Fracture Risks in Humans, September 09, 2022, 01:45 PM: Polygenic risk scores (September 9, 01:45 PM-02:15 PM), Exome sequencing at the extremes of BMD (September 9, 02:15 PM-02:45 PM)

13:30 – 13:50. Manifestaciones musculoesqueléticas y consecuencias a largo plazo de la infección por COVID, y riesgo de fracturas en la enfermedad renal crónica y sobrecarga de hierro.

Dra. Minerva Rodríguez García. 

[1069] Time variation fracture risk in dialysis and kidney transplant patients: A population-based study from the province of Quebec, Canada. September 11, 04:00 PM-04:15 PM.

[1115] increased fracture risk associated with iron overload: a population-based matched cohort study. September 12, 12:30 PM-12:45 PM.

RESUMIR: Special Session: Metabolic and Musculoskeletal Complications of SARS Cov-2: Considerations for Future Investigational Studies to Inform Clinical Care, September 10, 2022, 11:45-12:45 AM. Planning trials to investigate the long-term consequences of COVID-19. Design considerations for clinical studies investigating the musculoskeletal impact of long COVID; NIH initiatives Relating to Musculoskeletal Consequences of Long COVID;
Endocrine and Metabolic Manifestations of Acute and Post/Acute COVID 19;
Metabolic aspects of acute covid due to fibro-inflammatory responses and their impact on Long Covid.

13:50 – 14:00. Discusión

14:00-14:05. Clausura del curso

Dr. José A. Riancho Moral, Dra. Pilar Peris Bernal

Colabora: Gebro Pharma

Patrocinadores de la web
Laboratorios Rubió
Grupo Italfármaco
Gedeon Richter
Kyowa Kirin
Faes Farma
Meiji Pharma
Meiji Pharma